The FDA approval of Actelion’s
new pulmonary arterial
hypertension therapy Opsumit (PD
22 Oct), has reportedly made the
company a key takeover target.
Actelion’s existing product for the
PAH market, Tracleer, comes out of
patent in 2015 but the new product
has renewed interest from several
potential suitors including Bayer,
Novartis and GlaxoSmithKline,
according to a Bloomberg report.
The European Medicines Agency
has also recommended approving
the drug, with Actelion’s share price
up 62% so far this year.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Oct 13
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.